Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-17T15:26:18.707Z Has data issue: false hasContentIssue false

1 - Pathophysiology of nervous system diseases

from PART I - INTRODUCTION AND GENERAL PRINCIPLES

Published online by Cambridge University Press:  05 August 2016

Justin C. McArthur
Affiliation:
Departments of Neurology and Epidemiology, Johns Hopkins University Baltimore, MD, USA
Guy M. McKhann
Affiliation:
The Zanvyl Krieger Mind and Brain Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
W. Ian McDonald
Affiliation:
Institute of Neurology, University College London, Royal College of Physicians, London, UK
Peter J. Goadsby
Affiliation:
Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
Arthur K. Asbury
Affiliation:
University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Arthur K. Asbury
Affiliation:
University of Pennsylvania School of Medicine
Guy M. McKhann
Affiliation:
The Johns Hopkins University School of Medicine
W. Ian McDonald
Affiliation:
University College London
Peter J. Goadsby
Affiliation:
University College London
Justin C. McArthur
Affiliation:
The Johns Hopkins University School of Medicine
Get access

Summary

Since the last edition of this textbook, the field of Neurology and the Neurosciences has witnessed remarkable advances in the technologies available for the study of the brain and our concepts about the nervous system and its diseases. There has been progress in our ability to modify, prevent or treat these disease processes and to evaluate clinical outcomes, and in the resources available to handle and disperse data. There is, however, always a competition between the advancement of knowledge and the challenges of disease. We face challenges that demand that we put these advances to good use.

This introduction provides a brief, and necessarily incomplete, overview of some of the advances, and the many remaining challenges, for the study and treatment of diseases of the nervous system. A number of new therapeutic strategies have already been developed, and are already impacting on the quality of life of those with neurological disease. Many new treatments, both symptomatic and disease-modifying, are in the developmental pipeline. With the delineation of the human genome in 2001, a particular problem has emerged: the need to delineate protein production (proteomics) and protein modifications on a cellular basis. ‘The emerging challenge in understanding the pathogenesis of the neurodegenerative disorders will be to characterize and elucidate aberrant protein interactions in the affected cells’ (Martin, 1999). Future efforts will be focused on determining the tertiary structure of proteins which is currently determined using X-ray crystallography and nuclear magnetic resonance. Because of their relatively low through-put, complexity and high cost, these techniques have not generally been used for therapeutic targeting in drug discovery programmes. Recent technological advances, coupled with the information from human genome sequencing, are beginning to enable construction of a database to predict protein structure from sequence, and may be relevant for up to one-third of all gene targets (Christendat et al., 2000).

Global challenges in the developed and developing world

The world's aging population is increasingly affected by both acute and chronic neurological diseases. These include cerebrovascular disease, Alzheimer's disease and other dementias and Parkinson's disease. In the USA, the number of the very old (older than 85) is expected to increase sevenfold, from 2 million in 1990 to 14 million in 2040 and is increasingly vulnerable to chronic neurodegenerative disorders.

Type
Chapter
Information
Diseases of the Nervous System
Clinical Neuroscience and Therapeutic Principles
, pp. 3 - 13
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×